This article has been updated from a previous version

NEW YORK, Jan 24 - Agilent has licensed its custom in situ DNA microarrays to Applied Biosystems under a technology access agreement, the companies said Wednesday.

Applied Biosystems will use the microarrays for internal research and development only and did not gain a license to commercialize the Agilent arrays.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.